Jpmorgan Chase & CO Cyclo Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 153 shares of CYTH stock, worth $186. This represents 0.0% of its overall portfolio holdings.
Number of Shares
153
Previous 18
750.0%
Holding current value
$186
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CYTH
# of Institutions
22Shares Held
2.16MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA854KShares$1.04 Million0.47% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$586,4633.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA397KShares$483,9220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA160KShares$194,8930.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$134,22857.89% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $10.3M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...